GlaxoSmithKline Plc, a pharmaceutical business, said that their antibody treatment for Covid-19 is effective against the whole combination of mutations in the novel strain omicron.
The drugmaker in a statement said the tests done in-vitro against a pseudo-virus that recreates a synthesized version of omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations. The tests included all 37 mutations identified to-date in the spike protein.